Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Cumberland Settles Patent Suit Over Generic Acetadote

Cumberland Pharmaceuticals Inc., the maker of emergency medications, settled patent-infringement litigation with generic-drug makers Perrigo Co. and Paddock Laboratories LLC over Acetadote, an acetaminophen overdose treatment.

Cumberland, based in Nashville, Tennessee, sued Allegan, Michigan-based Perrigo and Minneapolis-based Paddock in May in federal court in Delaware to block their plan to market copies of Acetadote before the patent expires in 2026.

Under the settlement, “Paddock and Perrigo admit that the Acetadote patent is valid and enforceable,” and if another company introduces a generic copy, Cumberland will supply an authorized generic to Perrigo, according to a Cumberland filing yesterday with the U.S. Securities and Exchange Commission.

Acetadote is used in hospital emergency rooms to limit liver damage from life-threatening overuse of the pain reliever acetaminophen -- a leading cause of poisoning in the U.S., according to Cumberland.

Another lawsuit, in which Cumberland sued InnoPharma LLC over the same patent, is pending.

Perrigo fell 1.1 percent to $103.98 in Nasdaq Stock Market trading at 2:17 p.m. in New York. Cumberland was unchanged at $4.55. Paddock is closely held.

The case is Cumberland v. Paddock and Perrigo, 12-cv-619, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 8,148,356.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.